ARDC Research Link Australia Research Link Australia   BETA Research
Link
Australia
  • ARDC Newsletter Subscribe
  • Contact Us
  • Home
  • About
  • Feedback
  • Explore Collaborations
2026 ARDC Annual Survey is now open!

The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your interaction with the ARDC and use of our national research infrastructure and services. The survey will take approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure services including Reasearch Link Australia.

We will use the information you provide to improve the national research infrastructure and services we deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research Infrastructure Strategy (NCRIS) program.

Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.

Complete the 5 min survey now by clicking on the link below.

Take Survey Now

Thank you.

  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation

Need help searching? View our Search Guide.

Advanced Search

Current Selection
Research Topic : cancer genetics
Scheme : NHMRC Strategic Awards
Clear All
Filter by Field of Research
Oncology And Carcinogenesis (6)
Ophthalmology and optometry not elsewhere classified (4)
Medical and Health Sciences (3)
Oncology and carcinogenesis not elsewhere classified (3)
Public Health and Health Services (3)
Genetics Not Elsewhere Classified (2)
Genome Structure and Regulation (2)
Geriatrics And Gerontology (2)
Medical biochemistry - amino acids and metabolites (2)
Optical technology (2)
Applied immunology (incl. antibody engineering xenotransplantation and t-cell therapies) (1)
Clinical Sciences not elsewhere classified (1)
Craniofacial biology (1)
Geriatrics and Gerontology (1)
Health Promotion (1)
Medical biochemistry - inorganic elements and compounds (1)
Obstetrics And Gynaecology (1)
Oncology and Carcinogenesis (1)
Pharmacology and Pharmaceutical Sciences (1)
Respiratory Diseases (1)
Therapies And Therapeutic Technology (1)
Filter by Socio-Economic Objective
Search did not return any results.
Filter by Funding Provider
National Health and Medical Research Council (40)
Filter by Status
Closed (40)
Filter by Scheme
NHMRC Strategic Awards (40)
Filter by Country
Australia (4)
Filter by Australian State/Territory
VIC (4)
NSW (1)
  • Researchers (0)
  • Funded Activities (40)
  • Organisations (26)
  • Funded Activity

    QTL Linkage Analysis For Complex Human Traits In Twin Families

    Funder
    National Health and Medical Research Council
    Funding Amount
    $1,000,000.00
    Summary
    This project will focus on finding genes for common human diseases. Now that the human genome has been sequenced, the race is on to find out what the estimated 38,000 human genes do and which ones are associated with which diseases. Scattered throughout the genome are small variations in DNA sequence, some of which increase the odds of disease while others are protective.
    More information
    Funded Activity

    Genetic Factors For Osteoporosis

    Funder
    National Health and Medical Research Council
    Funding Amount
    $810,661.00
    Summary
    Osteoporosis is a common condition in which bone strength is reduced due to reduced amount and quality of bone. Reduced bone strength means an increased risk of fracture. Osteoporotic fractures occur in 1 in 2 women and 1 in 3 men in their lifetime, and the likelihood of suffering osteoporotic fracture increases with age. Most of the risk of developing osteoporosis is genetic, but few of the genes involved have been identified. Our goal is to identify those genes. We will complete recruitment an .... Osteoporosis is a common condition in which bone strength is reduced due to reduced amount and quality of bone. Reduced bone strength means an increased risk of fracture. Osteoporotic fractures occur in 1 in 2 women and 1 in 3 men in their lifetime, and the likelihood of suffering osteoporotic fracture increases with age. Most of the risk of developing osteoporosis is genetic, but few of the genes involved have been identified. Our goal is to identify those genes. We will complete recruitment and assessment of a cohort of 1500 postmenopausal women with either low or high bone mineral density from pre-existing population cohorts in Australia. A genomewide association study will then be performed on these cases. Associated genes in different datasets will then be investigated further in our cohort, and high-density SNP mapping performed to identify true associated variants. These studies should identify most genetic variants associated with BMD variation and low trauma fracture in the general community, allowing development of diagnostic-disease predictive genetic tests, and informing development of novel therapeutic agents for osteoporosis.
    Read more Read less
    More information
    Funded Activity

    International Cancer Genome Consortium

    Funder
    National Health and Medical Research Council
    Funding Amount
    $28,308,230.00
    More information
    Funded Activity

    Genetic And Evironmenal Risk Factors For Melanoma: Translation Into Behavioural Change

    Funder
    National Health and Medical Research Council
    Funding Amount
    $250,900.00
    Summary
    GenoMEL, formerly known as the Melanoma Genetics Consortium, has focused on the identification of familial high penetrance melanoma genes. The joint programme of research has been very successful in the identification of susceptibility genes and developing joint data collection for gene-environment interaction studies. In order to continue its proactive role, GenoMEL wishes to develop a multidisciplinary European platform, directed towards: 1. developing shared resources and activities 2. identi .... GenoMEL, formerly known as the Melanoma Genetics Consortium, has focused on the identification of familial high penetrance melanoma genes. The joint programme of research has been very successful in the identification of susceptibility genes and developing joint data collection for gene-environment interaction studies. In order to continue its proactive role, GenoMEL wishes to develop a multidisciplinary European platform, directed towards: 1. developing shared resources and activities 2. identification of new susceptibility genes and understanding the role of these genes in tumours 3. investigation of genotype-phenotype interaction and gene-environment interaction for known susceptibility genes 4. investigation of attitudes to risk of melanoma in Europe, and translation of that risk perception into behavioural change 5. spreading excellence by creating a widely accessible web-based content management system (CMS) to address prevention, early detection, dealing with the diagnosis of melanoma and genetic counselling. Through GenoMEL's jointly executed research, groups will support the network's goal to maintain excellence in research, increase institutional integration and create an enduring structure of translational melanoma genetics research in Europe and other countries. European integration will enhance dialogue, disseminate expertise and resources, provide training and allow mobility of scientists within Europe. It is aimed to keep the network open and dynamic by adding new partners, especially in Eastern Europe where melanoma incidence rates may rise most precipitously in the near future, if the expected increase in wealth results in greater levels of sun exposure. There will be participation from four new European groups and others from Australia, the USA and Israel to capitalize on latitudinal (sun exposure) differences between these groups.
    Read more Read less
    More information
    Funded Activity

    Enterovirus 71 In The Asia-Pacific Region: Reverse Genetic Approaches To Virus Surveillance And Vaccine Development.

    Funder
    National Health and Medical Research Council
    Funding Amount
    $690,833.00
    Summary
    In this research the team will use advanced biotechnological techniques to study the distribution and virulence markers of an important emerging infectious disease, enterovirus 71 encephalitis, in the Asia-Pacific region. The knowledge and technical advances derived from this study will be shared with neighbouring countries in order to conduct sensitive surveillance for this infection throughout the region. The study's other major aim is to use cutting-edge biotechnological techniques to develop .... In this research the team will use advanced biotechnological techniques to study the distribution and virulence markers of an important emerging infectious disease, enterovirus 71 encephalitis, in the Asia-Pacific region. The knowledge and technical advances derived from this study will be shared with neighbouring countries in order to conduct sensitive surveillance for this infection throughout the region. The study's other major aim is to use cutting-edge biotechnological techniques to develop a genetically defined, live attenuated vaccine strain. Candidate vaccine strains will be tested for their effectiveness in both cell culture-based and animal models.
    Read more Read less
    More information
    Funded Activity

    Analysis Of Mouse Nervous System Development And Disease Using SAGE

    Funder
    National Health and Medical Research Council
    Funding Amount
    $3,997,000.00
    More information
    Funded Activity

    Risk Of Brain Cancer From Exposure To Radiofrequency Fields In Childhood And Adolescence

    Funder
    National Health and Medical Research Council
    Funding Amount
    $708,426.00
    Summary
    Mobile phone use is increasing in Australia, especially among children and young adults. This study is the Australian arm of an international multi-centre study that will investigate exposure to radiofrequency radiation from mobile phone use during childhood and adolescence and later onset of brain tumours in people between the ages of 10 and 24 years. There is considerable community concern and scientific interest about possible health effects from mobile phone exposure in young people and this .... Mobile phone use is increasing in Australia, especially among children and young adults. This study is the Australian arm of an international multi-centre study that will investigate exposure to radiofrequency radiation from mobile phone use during childhood and adolescence and later onset of brain tumours in people between the ages of 10 and 24 years. There is considerable community concern and scientific interest about possible health effects from mobile phone exposure in young people and this multi-centre study will provide important information about such cancer risks.
    Read more Read less
    More information
    Funded Activity

    Therapeutic Cancer Vaccines

    Funder
    National Health and Medical Research Council
    Funding Amount
    $180,923.00
    Summary
    This project will develop and test a new cell-based anticancer vaccine for patients with Prostate cancer. The collaboration will involve French, Italian, Austrian and German researchers. Blood will be taken from patients in the clinical trial, the patient's cells will be converted into a cell vaccine, and these cells will be labelled with a radioactive tracer and re-injected into the host. Australian researchers at the Centre for Blood Cell Therapies at the Peter MacCallum Cancer Centre will the .... This project will develop and test a new cell-based anticancer vaccine for patients with Prostate cancer. The collaboration will involve French, Italian, Austrian and German researchers. Blood will be taken from patients in the clinical trial, the patient's cells will be converted into a cell vaccine, and these cells will be labelled with a radioactive tracer and re-injected into the host. Australian researchers at the Centre for Blood Cell Therapies at the Peter MacCallum Cancer Centre will then track the performance of the vaccine using advanced diagnostic imaging to determine how effective the vaccine is in stimulating the body's own defence mechanisms to fight the cancer. Multiple versions of the treatment are being developed by the international collaboration and the Institute will help determine which approach is most effective in combating cancer. The Peter MacCallum Cancer Centre is the foremost centre worldwide for this type of cell tracking study.
    Read more Read less
    More information
    Funded Activity

    Developing And Testing A Pain Management Program For Family Caregivers Of Advanced Cancer Patients

    Funder
    National Health and Medical Research Council
    Funding Amount
    $119,500.00
    Summary
    To improve cancer patients' and family carers' knowledge and attitudes about pain management. A secondary aim is to examine the effect of a pain education program (PEP) on patients' actual pain experiences. This study builds on pilot data indicating that a pain education program (PEP) for family carers of cancer patients in a home based palliative service is effective in improving family carers' knowledge of pain management and family carers' attitudes toward managing the patient's pain. The PEP .... To improve cancer patients' and family carers' knowledge and attitudes about pain management. A secondary aim is to examine the effect of a pain education program (PEP) on patients' actual pain experiences. This study builds on pilot data indicating that a pain education program (PEP) for family carers of cancer patients in a home based palliative service is effective in improving family carers' knowledge of pain management and family carers' attitudes toward managing the patient's pain. The PEP will be tested with both patients with progressive or recurrent cancer and their family carers, taking into account three recommendations arising from the pilot study: Both patients and family carers should be included in the education sessions to ensure that they receive the same information because the attitudes and behaviours of those close to the patient can directly influence outcomes; Recruitment should occur at an early stage of the illness rather than the palliative stage so that patients will be well enough to participate in the education sessions and the information provided will be useful for a longer period of time; Education sessions should be short and be delivered in the outpatient oncology settings, which is more cost-effective and typical of the way that the intervention will be delivered in practice, if found to be effective.
    Read more Read less
    More information
    Funded Activity

    Genome-wide Combined Linkage-association Scan Of Multiply Phenotyped Twin Sibships

    Funder
    National Health and Medical Research Council
    Funding Amount
    $1,920,000.00
    Summary
    We have a large ongoing study of adolescent twins, their siblings and parents who are multiply phenotyped in many domains including melanoma risk factors, serum biochemistry, and cognition. We used our first Medical Genomics grant to obtain a 5cM linkage scan for>500 families and have identified linkage peaks for many different phenotypes. To fine map these it will be most efficient to carry out a genome-wide association scan. We request funds to type a 500k SNP chip on 1000 individuals.
    More information

    Showing 1-10 of 40 Funded Activites

    • 1
    • 2
    • 3
    Advanced Search

    Advanced search on the Researcher index.

    Advanced search on the Funded Activity index.

    Advanced search on the Organisation index.

    National Collaborative Research Infrastructure Strategy

    The Australian Research Data Commons is enabled by NCRIS.

    ARDC CONNECT NEWSLETTER

    Subscribe to the ARDC Connect Newsletter to keep up-to-date with the latest digital research news, events, resources, career opportunities and more.

    Subscribe

    Quick Links

    • Home
    • About Research Link Australia
    • Product Roadmap
    • Documentation
    • Disclaimer
    • Contact ARDC

    We acknowledge and celebrate the First Australians on whose traditional lands we live and work, and we pay our respects to Elders past, present and emerging.

    Copyright © ARDC. ACN 633 798 857 Terms and Conditions Privacy Policy Accessibility Statement
    Top
    Quick Feedback